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Background. We examined longitudinally the course and predictors of treatment resistance in a large cohort of ﬁrst-
episode psychosis (FEP) patients from initiation of antipsychotic treatment. We hypothesized that antipsychotic treat-
ment resistance is: (a) present at illness onset; and (b) differentially associated with clinical and demographic factors.
Method. The study sample comprised 323 FEP patients who were studied at ﬁrst contact and at 10-year follow-up. We
collated clinical information on severity of symptoms, antipsychotic medication and treatment adherence during the fol-
low-up period to determine the presence, course and predictors of treatment resistance.
Results. From the 23% of the patients, who were treatment resistant, 84% were treatment resistant from illness onset.
Multivariable regression analysis revealed that diagnosis of schizophrenia, negative symptoms, younger age at onset,
and longer duration of untreated psychosis predicted treatment resistance from illness onset.
Conclusions. The striking majority of treatment-resistant patients do not respond to ﬁrst-line antipsychotic treatment
even at time of FEP. Clinicians must be alert to this subgroup of patients and consider clozapine treatment as early as
possible during the ﬁrst presentation of psychosis.
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Introduction
It is widely established that treatment response in
schizophrenia is heterogeneous (Lieberman et al.
1993; Levine et al. 2012); whilst a good number of
patients achieve remission, a considerable proportion
remains actively and persistently psychotic despite
optimal pharmacological treatment. It remains, how-
ever, unknown whether these patients are treatment
resistant from the illness onset (TRO), or whether
they gradually become resistant as illness progresses
in the context of multiple episodes, chronic exposure
to medication or neurochemical sensitization. We
have previously demonstrated that dopamine dysfunc-
tion is not evident in treatment-resistant patients
(Demjaha et al. 2012, 2014) and this, together with the
evidence linking various underlying neurodevelop-
mental factors to treatment resistance (McCreadie
et al. 1989; Robinson et al. 1999), may suggest that in
this distinct subgroup, dopamine-blocking antipsycho-
tics are ineffective right from the beginning of illness.
In support of this, ﬁrst-episode psychosis (FEP) studies
have established that even during the ﬁrst episode of
illness where treatment response to antipsychotic
medication tends to be greater; up to one-quarter of
patients continue to have persistent symptoms despite
adequate treatment (Lieberman et al. 1993; Agid et al.
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2011; Schennach et al. 2012). Furthermore, an earlier
study of patients with chronic illness has documented
that the majority of ‘poor responders’ were unrespon-
sive throughout their illness (Kolakowska et al. 1985).
Other authors, however, have claimed that treatment
resistance evolves in the context of a long duration of
untreatedpsychosis (DUP)ormultipleepisodesof illness,
suggesting that psychotic episodes have a neurotoxic
effect, which gave support to the ‘neurodegeneration
hypothesis’ of antipsychotic treatment resistance
(Loebel et al. 1992).
With respect to predictors of treatment resistance,
the literature to date remains sparse and inconsistent.
Although greater severity of negative symptoms,
younger age at onset, poor pre-morbid functioning,
male gender and a longer DUP have all been linked
to treatment resistance (McCreadie et al. 1989;
Lieberman et al. 1993; Robinson et al. 1999), these stud-
ies have mostly focused on poor outcome or poor
response to antipsychotic treatment, and have not dis-
tinguished between different subtypes of treatment
resistance, which may account for disparity in results.
Identifyingwhether andwhich patients are likely to be
TRO is of fundamental clinical importance, particularly
with regards to introducing as early as possible the only
antipsychotic effective in these patients (Kane et al.
1988). Thus, we examined the course of treatment resist-
ance over a 10-year period, in a large cohort of FEP
patients.Additionally,we investigatedpredictorsof treat-
ment resistance including gender, mode of onset, ethni-
city, DUP and negative symptoms, exclusively in those
patients who were resistant to antipsychotic treatment
from the illness onset. Based on evidence to date, we
hypothesized that antipsychotic treatment resistance is:
(a) present at illnessonset; and (b) differentiallyassociated
with clinical and demographic factors.
Method
Study sample
Data originate from AESOP-10, a 10-year longitudinal,
population-based study of incident cases of psychosis
from deﬁned catchment areas. At baseline, all patients
aged 16–64 years who presented with FEP over a
2-year period in centres in southeast London and
Nottingham (UK) were invited to take part at approxi-
mately 10 years post-inclusion. Ethical approvals for
both the baseline and follow-up studies were obtained
from the local research ethics committees. At baseline,
patients gave consent to be re-contacted for follow-up.
The analytic sample comprised 323 patients for
whom there was complete information on medication,
adherence to treatment and symptom ratings over the
10-year follow-up period (Fig. 1). A comparison of
cases with adequate treatment information (n = 323)
and those without complete information (n = 163) did
not reveal any notable differences in age, age of
onset, gender, ethnicity, diagnosis, mode of onset,
DUP or negative symptoms. Similarly, there were no
statistically signiﬁcant differences in these parameters
between cases with adequate treatment information
(n = 323) and the rest of the total sample including 71
cases lost to follow-up (n = 234).
Baseline clinical assessment
Psychopathology was assessed at ﬁrst contact with
psychiatric services using the Schedules for Clinical
Assessment in Neuropsychiatry (SCAN; World
Health Organization, 1994). Diagnoses were estab-
lished according to International Classiﬁcation of
Diseases (ICD)-10 diagnostic criteria for research
(World Health Organization, 1992) during clinical con-
sensus meetings. There was 80% inter-rater agreement
on diagnostic category.
Using factor analysis, baseline symptoms were cate-
gorized into ﬁve psychopathological dimensions
(manic, reality distortion, negative, depressive and dis-
organized) (Demjaha et al. 2009). Age at onset was
established as the age at which ﬁrst psychotic symp-
toms appeared. Mode of onset was rated, using the
World Health Organization (WHO) Personal and
Psychiatric History Schedule, according to two cat-
egories: acute (psychotic symptoms appeared incre-
mentally within 1 month); and insidious (psychotic
symptoms appeared incrementally over a period of
more than 1 month). DUP was deﬁned as the period
in weeks from the onset of psychosis to ﬁrst contact
with statutory mental health services.
Follow-up clinical assessments
Length of follow-up was deﬁned as the period between
ﬁrst presentation to psychiatric services and date of
follow-up assessment. Clinical information was
obtained through subject interview, case-note review
and informant interview, and recorded using the
WHO Life Chart, which was adapted to include add-
itional information on service contacts and anti-
psychotic treatment (Harrison et al. 2001;
Morgan et al. 2014). Mental state was assessed with
the SCAN.
Case histories were reconstructed over the follow-up
period to complete the Life Chart. This involved close
examination of medication charts, medical records
and clinical documentation. The start and end dates
of all prescribed antipsychotic medication, dosage,
adherence to treatment, and the reason for change or
termination, were recorded.
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In line with National Institute for Health and Care
Excellence (NICE) (National Institute for Health and
Care Excellence, 2014) criteria, patients who had
received two sequential antipsychotic trials, each of
at least 4 weeks’ duration at a daily dose of 400–600
mg of chlorpromazine equivalents, but continued to
have persistent psychotic symptoms, which was
deﬁned as having a rating of at least moderate severity
on one or more positive symptoms as rated by SCAN,
and despite recorded adherence to medication, were
classiﬁed as ‘treatment resistant’.
Patients were classiﬁed as TRO if they met criteria for
treatment resistance following the ﬁrst two trials of
antipsychotic medication. Patients with ‘delayed-onset
treatment resistance’ (DOTR) were deﬁned as those
who, following initial response to treatment, subse-
quently met criteria for treatment resistance.
Treatment response was deﬁned as a state, of at least
6 months’ duration, in which no symptoms or only
symptoms of mild severity, not interfering with daily
functioning, were experienced (Andreasen et al. 2005).
Statistical analysis
Analyses were performed using SPSS (version 22.0;
SPSS Inc., USA) and R 3.1 (R Core Team, 2014).
Fig. 1. Study sample derived from the ÆSOP-10. There were no statistically signiﬁcant differences (at p < 0.05) in terms
of gender, ethnicity, study centre, duration of untreated psychosis (DUP) or diagnosis between subjects initially recruited
(n = 557) and those with complete follow-up assessment (n = 412). The subjects with complete (n = 323) and incomplete
treatment information (n = 234) did not differ signiﬁcantly in terms of gender, ethnicity, DUP or diagnosis; however, there
were signiﬁcant differences in study centre (p = 0.002).
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Descriptive data are reported as frequencies and per-
centages or means and standard deviations as appro-
priate. Demographic and clinical characteristics were
compared between subjects with complete and incom-
plete clinical information using χ2, Fisher’s exact or
independent-samples t tests as appropriate.
Regression analyses
First step. To investigate the predictors of TRO we per-
formed univariable logistic regressions for predictor
variables and the main outcome ‘TRO’. Based on evi-
dence to date we have included the following predic-
tors: age at onset, gender, ethnicity, diagnoses, DUP,
mode of onset and negative symptom dimension
derived by factor analysis of baseline symptoms
rated by SCAN. Odds ratios (ORs) and 95% conﬁdence
intervals are reported (see Table 2).
Second step. We performed multivariable analyses to
describe the relationship between (‘treatment resist-
ance’) TRO and clinical and demographic variables,
controlling for gender, age of onset and type of diagno-
sis, to identify the best set of predictors. However,
since our sample size and the observed number of
TRO patients relative to the number of predictors in
the ﬁnal data were relatively modest, the subset
model selection procedures would violate every prin-
ciple of statistical estimation and hypotheses testing.
Thus, we penalized logistic regression to obtain stable
parameters and improve prediction accuracy (Harrell,
2015). The LASSO regression approach was used
which penalized the sum of the absolute values of the
regression coefﬁcients and thus shrank regression coefﬁ-
cients towards 0. The shrinkage penalty λwas chosen by
a repeated 10-fold cross-validation method (Hastie et al.
2009) and implemented in the R package glmnet.
Model performance
Penalized regression methods do not provide standard
errors or other inferential statistics. We assessed the
predictive performance of the ﬁnal penalized logistic
regression model using the Brier score and percentage
explained deviance (or McFadden’s pseudo R2) as
measures of the overall prediction accuracy.
Correction for optimism
We used the same dataset to ﬁt the model and to assess
its predictive ability and validated our model by fol-
lowing recommendations by Harrell (2015) to correct
for optimisms of our estimates using bootstrapping
procedures. This estimate of optimism is then sub-
tracted off the naive estimate of regression parameter
estimates, Brier score and McFadden pseudo R2 of
our model.
Results
Rigorous examination of clinical information including
the medication data, severity of symptoms and informa-
tion on adherence to treatment recorded over a 10-year
period revealed that 74 patients (23%) met criteria for
treatment resistance. The majority of these patients (n =
62/74; 84%),were TRO, as they had not responded to anti-
psychotic medication from the initiation of treatment; 212
(66%) met criteria for treatment response (responders).
The remaining 37 (11%) had never received an adequate
trial of antipsychotic medication and therefore could not
be included in either category (unclassiﬁed; UC).
The 286 subjects that could be classiﬁed according to
response (i.e. meeting response criteria) and those with
incomplete information, comprising in addition 37 UC
(total n = 271) did not differ in any of these parameters.
Clinical and demographic characteristics of the ana-
lytic sample are presented in Table 1.
Qualitative exploration revealed that patients with
DOTR had a later age at onset by approximately 4
years than TRO patients [mean age: 28.3 (S.D. = 12.2)
v. 24.8 (S.D. = 6.3) years, respectively]. All DOTR
patients had a diagnosis of schizophrenia, and most
(n = 9, 75%) had received clozapine. They developed
treatment resistance on average 5 years after initial
treatment, and after an average of four admissions
(range 1–19).
Of the patients in the treatment-resistant group, 50
received clozapine; we identiﬁed 12 as clozapine treat-
ment resistant (CTR), and 14 patients as clozapine
responders. Patients were considered CTR if they had
persistent symptoms of at least moderate severity des-
pite complying with clozapine treatment for at least 6
months (Meltzer, 1997) at a daily dose of at least
400 mg. More than a third (n = 18) could not be included
in either group as they had received a suboptimal trial of
clozapine. For the remaining six patients, sufﬁcient clin-
ical and response data to determine response were lack-
ing. Almost all CTR patients were men (n = 11), all had
a diagnosis of schizophrenia (n = 12), and they had very
similar age at onset comparedwith clozapine responders
[meanage: 24.2 (S.D. = 6.8) v. 24.3 (S.D. = 7.5) years, respect-
ively]. CTR patients received on average 700 mg of
clozapine daily.
Predictors of TRO
Univariable logistic regressions
The odds of developing TRO were higher among those
with diagnosis of schizophrenia, earlier onset of psych-
osis, higher scores on negative symptoms, insidious
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mode of onset and longer DUP. Furthermore, women
were less likely to be treatment resistant. No effect of
ethnicity was detected. For details, see Table 2.
The effect was strongest for negative symptoms (OR
1.24, p = 0.003); the odds frombeingTRO for a patient pre-
senting with four negative symptoms were 2.36 higher,
and for a person with nine symptoms 6.9 times higher,
compared with a patient with no negative symptoms.
Multivariable LASSO regression (Table 3)
The multivariable penalized LASSO regression with
all variables included as potential predictors revealed
that only diagnosis, younger age of onset, negative
symptoms and longer DUP remained in the ﬁnal
model. The optimism corrected OR for negative
symptoms was 1.088. Thus, the predicted odds of
treatment resistance were 1.4 higher for a patient
with four negative symptoms and 2.13 higher for a
patient with nine negative symptoms, compared
with a patient with no negative symptoms after con-
trolling for mode of onset, type of diagnosis, age of
onset and DUP. Similarly, the ﬁnal optimism
corrected model explained 10.0% of the deviance
and the Brier score was 0.146, suggesting a moderate
explanatory power.
UC patients
In all, 37 patients could not be classiﬁed according to
their drug response; of these, 20 received only one
antipsychotic during the course of their illness, and
the remaining 17 received two or more antipsychotics
at the sub-therapeutic dose. The majority of these
patients had a diagnosis of schizophrenia (n = 30),
and were male (n = 20). This group had a later age
at onset by approximately 7 years than TRO patients
[mean age: 0.31.5 (S.D. = 11.4) v. 24.8 (S.D. = 6.3) years,
respectively].
Discussion
To our knowledge this is the ﬁrst and the largest longitu-
dinal FEP study to investigate the course and predictors
of TRO. We demonstrated that the great majority of treat-
ment-resistant patients did not achieve symptomatic
Table 1. Clinical and demographic characteristics of the analytic sample
Responders (n = 212) TR (n = 74) TRO (n = 62) DOTR (n = 12)
Mean age of onset, years (S.D.) 30.1 (10.5) 25.4 (7.7) 24.8 (6.3) 28.3 (12.2)
Gender
Male 114 (53.8) 53 (71.6) 44 (71.0) 9 (75.0)
Female 98 (46.2) 21 (28.4) 18 (29.0) 3 (25.0)
Ethnicity
White British 91 (42.9) 31 (41.9) 26 (41.9) 5 (41.7)
Black Caribbean 56 (26.4) 22 (29.7) 19 (30.6) 3 (25.0)
Black African 24 (11.3) 12 (16.2) 10 (16.1) 2 (16.7)
White other 13 (6.1) 3 (4.1) 2 (3.2) 1 (8.3)
Asian 17 (8.0) 3 (4.1) 3 (4.8) 0 (0.0)
Other 11 (5.2) 3 (4.1) 2 (3.9) 1 (8.3)
Mode of onset
Acute 97 (45.8) 25 (33.8) 17 (27.4) 8 (66.7)
Insidious 87 (41.0) 36 (48.6) 33 (53.2) 3 (25.0)
Unknown 28 (13.2) 13 (17.6) 12 (21.4) 1 (8.3)
Diagnosis
Schizophrenia 140 (66.0) 70 (94.6) 58 (93.5) 12 (100)
Manic 39 (18.4) 2 (2.7) 2 (3.2) 0 (0.0)
Depressive 33 (15.6) 2 (2.7) 2 (3.2) 0 (0.0)
Education
Any qualiﬁcation 149 (70.3) 44 (60.5) 35 (57.5) 9 (75.0)
No qualiﬁcation 56 (26.4) 24 (32.4) 21 (33.9) 3 (25.0)
Unknown 7 (3.3) 6 (8.1) 6 (9.7)
Median DUP, weeks (interquartile range) 5.7 (2.0–22.8) 23.8 (4.4–101.1) 26.3 (4.4–104.3) 11.5 (4.6–32)
Mean length of follow-up period, years (S.D.) 9.8 (2.12) 9.3 (2.21) 9.6 (2.31) 10.9 (1.04)
Data are given as number of participants (percentage) unless otherwise indicated.
TR, Treatment resistant; TRO, treatment resistant from onset; DOTR, delayed-onset treatment resistant; S.D., standard devi-
ation; DUP, duration of untreated psychosis.
Antipsychotic treatment resistance in ﬁrst-episode psychosis 5
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0033291717000435
Downloaded from https:/www.cambridge.org/core. KU Leuven University Library, on 29 May 2017 at 11:14:19, subject to the Cambridge Core terms of use, available at
remission following ﬁrst two trials of antipsychotic
treatment.
Heterogeneity of treatment resistance
Our ﬁnding that over 80% of treatment-resistant
patients have never shown response to antipsychotic
treatment despite adequate adherence suggests that
treatment resistance may be an enduring trait in
these patients. This ﬁnding has recently been repli-
cated in a subsequent study that found 70% of
treatment-resistant patients to be resistant from FEP
(Lally et al. 2016) and in addition is consistent with
results from a FEP follow-up trial that documented
that over 8% of patients did not respond to medication
and were ‘never well enough to be discharged’
(MacMillan et al. 1986). Furthermore, Loebel et al.
(1992), in their 3-year follow-up FEP study, documen-
ted that between 5 and 25% of their patients had per-
sistent positive symptoms during the initial illness
phase. Similarly, Agid et al. (2011) concluded that
80% of patients had treatment-resistant schizophrenia
from illness onset, which largely corroborates our
results. The ﬁnding that the majority of treatment-
resistant patients do not respond from illness onset
has direct clinical relevance; these are the patients
that should be commenced on clozapine at the earliest
possibility, particularly in light of the clozapine under-
utilization identiﬁed in a recent national audit (Patel
et al. 2014), and evidence that the chances of respond-
ing to clozapine are higher if it is introduced earlier in
their illness (Kane et al. 1988).
Notwithstanding the fact that a high percentage of
patients are TRO, still a small, but not negligible, pro-
portion of patients developed resistance to treatment
later in the illness. Thus, there may well be one form
of treatment resistance that manifests at the onset
and another that develops during the course of the dis-
order, as previously advocated in the treatment resist-
ance literature (Meltzer, 1997; Sheitman & Lieberman,
1998). Whether the development of treatment resistance
is due to the effect of repeated exposure to medication,
dopamine sensitization, effects of neurodegeneration,
or a combination of these factors remains to be
answered. There is, however, some evidence from ani-
mal studies that chronic treatment with dopamine-
blocking antipsychotics induces dopamine receptor
up-regulation, which could then reduce the efﬁcacy of
antipsychotic treatment and lead to breakthrough dopa-
mine super-sensitivity. This could predispose some
patients to becoming treatment resistant following
repeated and chronic exposure to antipsychotic treat-
ment, which warrants future investigations in larger
samples.
Although our study did not identify patients whose
response to medication improved during the course
of illness, there is evidence for a third group of
treatment-resistant patients who may achieve
Table 2. Univariable logistic regression predicting the effect of demographic and clinical factors on treatment resistance
Variable OR (95% CI) p n
Gender
Male 1
Female 0.48 (0.25–0.86) 0.014 274
Diagnosis χ2271 = 22.24, p < 0.0001 274
Schizophrenia 1
Manic psychosis 0.12 (0.02–0.42) 0.005
Depressive psychosis 0.15 (0.02–0.5) 0.01
Age of onset 0.93 (0.89–0.97) <0.0001 266
Negative symptoms 1.24 (1.08–1.42) 0.003 239
Mode of onset
Acute 1 240
Insidious 0.13 (1.44–0) 0.018
Ethnicity χ22 = 0.73, p = 0.69 274
White 1
Black 1.29 (0.72–2.31) 0.4
Asian 1.05 (0.23–3.64) 0.94
Ethnicity (two categories)
White 1
Non-white 1.26 (0.72–2.24) 0.42
DUP 1.004 (1.001–1.006) 0.002 265
OR, Odds ratio; CI, conﬁdence interval; DUP, duration of untreated psychosis.
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spontaneous remission or start responding to treat-
ment later in life (Meltzer, 1997). This is in line with
observations that older patients with schizophrenia
require much less intensive maintenance antipsychotic
treatment than their younger counterparts and could
perhaps be explained by the fact that the dopamine
system is age dependent, with signiﬁcant reductions
in dopaminergic transmission in older subjects being
observed (Dreher et al. 2008). The fact that the mean
age in our study is 30.5 years could explain the nega-
tive ﬁnding.
Finally, 11% of our sample had never received an
adequate trial of antipsychotic medication. It has
been advocated that patients at initial stages of their ill-
ness tend to respond to a lower dose of medication
(Gardner et al. 2010), with published guidelines for
medication response in FEP recommending a lower
threshold of 300 mg chlorpromazine equivalents
(Buchanan et al. 2010). Therefore UC patients could
have been classiﬁed as a responder at lower than
threshold dosage. However, all our 37 UC cases have
been persistently symptomatic; therefore we could
not classify them as responders. On the other hand,
had they received another antipsychotic, or higher
dose of existing medication, some may have well
responded to medication, but the reasons for
inadequate treatment in this group remain unknown
and warrant future exploration.
Predictors of TRO
Both negative symptoms and age at onset have been
linked to treatment resistance (Kolakowska et al.
1985; McCreadie et al. 1989; Meltzer et al. 1997;
Robinson et al. 1999). Contrary to our expectations,
the study by Lally et al. (2016) did not ﬁnd association
with negative symptoms, which could be due to
the fact that they used the Positive and Negative
Syndrome Scale (PANSS) negative subscale that does
not incorporate all negative symptoms such as motor
retardation and active social avoidance.
Treatment resistance deﬁnitions to date have largely
focused on persistent positive symptoms. In view of
the negative symptom signiﬁcance for treatment resist-
ance, consideration should be given to their inclusion
to determine treatment resistance. The Treatment
Response and Resistance in Psychosis (TRRIP)
Working Group has recently recommended the use
of sub-speciﬁc ‘negative’ and ‘cognitive’ domains in
addition to ‘positive’ domain when deﬁning treatment
resistance (Howes et al. 2016).
The ﬁnding that treatment-resistant patients are
more likely to be younger at onset and have more
negative symptoms adds some weight to the notion
of the neurodevelopmental aetiology of treatment
resistance, whereby disruptions during neurodevelop-
ment may affect pathophysiology even before the
psychotic symptoms manifest. Our ﬁnding that longer
DUP predicts treatment resistance is in line with evi-
dence from a comprehensive systematic review that
documented the association between longer DUP and
poor outcome (Marshall et al. 2005).
Methodological considerations
Data on medication, compliance and psychopathology
collected over the follow-up period could have been
affected by information bias. However, the WHO Life
Chart is considered a reliable instrument for follow-up
studies (Susser et al. 2000). In terms of symptomatology,
there may be an overestimation of response, since
patients who do not show signiﬁcant behavioural dis-
turbance may be rated by clinicians as ‘stable’, even
when they are still symptomatic (Kolakowska et al. 1985).
We suggest that TRO may be neurodevelopmental
in origin, in light of its association with negative symp-
toms and younger age at onset, but acknowledge that a
small number of neurodevelopmental factors were
evaluated. Thus, this is preliminary evidence that
needs to be tested in future studies. Further, we advo-
cate early use of clozapine, but in view of its adverse
effects, it is essential that non-response to ﬁrst-line
Table 3. Multivariable LASSO logistic regression predicting the
effect of demographic and clinical factors on treatment resistancea
Variable B Odds ratio
Intercept −0.74
Gender
Male N.A.
Female N.A.
Diagnosis
Schizophrenia 0 1
Manic psychosis −0.90 0.41
Depressive psychosis −0.65 0.52
Age of onset −0.029 0.97
Negative symptoms 0.085 1.088
Mode of onset
Acute 0 1
Insidious 0.247 1.28
Ethnicity
White –
Non-white –
DUP 0.0013 1.0013
N.A., Not applicable; DUP, duration of untreated
psychosis.
a Regression coefﬁcients (for prediction models) and odds
ratios corrected for optimism using the method according to
Harrell (2015). Due to the small sample size of Asians, eth-
nicity was collapsed into white and non-white groups.
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antipsychotics is ﬁrmly established and our results are
replicated and extended in studies that test larger num-
ber of treatment resistance predictors.
We further acknowledge that due to the small num-
ber of DOTR patients, only qualitative explorations
were possible. This important group needs further
evaluation in larger multicentre studies.
It has been suggested that time to response may vary
between FEP and chronic patients with schizophrenia;
there is some evidence that most FEP patients respond
between weeks 8 and 16 of treatment with a single anti-
psychotic medication (Gallego et al. 2011). In our study,
however, all TRO were persistently symptomatic
throughout the follow-up period, and most have been
on a single antipsychotic for longer than 18 weeks.
Another limitation relates to the treatment adherence
measurements. The blood levels were not performed
routinely for these patients, so we could not be certain
of ensured compliance other than in cases, where
depot medication was prescribed. However, we have
only included patients for whom we had recorded
data on adequate adherence collated from medication
charts, medical records and clinical documentation
Finally, LASSO regression needs a complete case
dataset. The sample size thus in our analysis has
been reduced by 20%. However, pairwise comparison
of patients with complete and incomplete datasets
did not reveal any signiﬁcant differences for any demo-
graphic or clinical variables.
Nevertheless, we have examined prospectively, dur-
ing the most critical phase of illness, the course and
subtypes of treatment resistance in a large and rela-
tively homogeneous sample of FEP patients, who
were free of the effects of prior antipsychotic treatment
and yielded results of theoretical and clinical
importance.
Conclusion
Our data indicate that the great majority of treatment-
resistant patients are resistant from illness onset. We
believe that this form of treatment resistance is a stable
phenotype of illness marked by more severe negative
symptoms and younger age at onset. Our ﬁndings
will hopefully alert clinicians to the surprisingly high
prevalence of treatment resistance at the initial presen-
tation of psychosis, and assist with early detection of
patients who are most likely not to respond to dopa-
minergic blockade. This has important implications
for treatment paradigms in FEP, particularly with
regards to introducing clozapine as early as possible fol-
lowing ﬁrst presentation with the aim of preventing
years of enduring treatment resistance and increasing
functional disability. However, in view of adverse side
effects of clozapine, future studies need to replicate
our ﬁndings in larger treatment-resistant samples and
examine all relevant predictors in order to detect accur-
ately patients who are likely to be at risk of not respond-
ing to treatment.
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